Story

US Prescription Volume Growth Slowed to 1.5% in Late July, Morgan Stanley Reports

ENTHMSVIIDZHZH-TWJAKOHI
Aug 7, 20262 min read
US Prescription Volume Growth Slowed to 1.5% in Late July, Morgan Stanley Reports
Text size
Background

U.S. prescription drug volume growth slowed in the final week of July, rising 1.5% year-over-year, according to a weekly market analysis from Morgan Stanley. The data, for the week ending July 31, represents a deceleration from the 2.0% growth recorded in the prior week but remains above the 12-week average growth rate of 1.3%.

Overall Market Trends

The report highlighted several key metrics for the U.S. pharmaceutical market. On a week-over-week basis, total prescriptions declined by 0.5%, following a 0.4% dip in the preceding week. The rolling four-week total prescription volume showed a slight year-over-year contraction of -0.2%.

Extended units, a measure of the total quantity of medication dispensed, grew 1.1% year-over-year, lagging the growth in total prescription numbers. This suggests a potential shift in the mix of drugs being prescribed.

New Drug Launch Trajectories

Morgan Stanley's analysis provided updates on the commercial launches of several key drugs, which are closely watched by investors:

Sample IUX Markets – In-articleAd
  • Bristol Myers Squibb (BMY): Prescriptions for its schizophrenia treatment, Cobenfy, reached approximately 3,370, up from about 3,290 the previous week. The bank estimates that to meet the 2026 consensus sales forecast of $271 million, total prescriptions would need to reach roughly 186,000, assuming a net price of around $1,450.
  • Gilead Sciences (GILD): Total prescriptions for Yeztugo were largely flat at 1,890. The drug maintains a strong persistence rate of over 70% and has secured 95% payer coverage. Morgan Stanley's U.S. sales estimate of $1.049 billion is notably higher than the market consensus of $988 million.
  • Vertex Pharmaceuticals (VRTX): Journavx, a treatment for acute pain, saw prescriptions rise to 26,970 from 26,450. Vertex noted that this IQVIA data does not capture hospital prescriptions, which are expected to account for about 45% of the drug's volume.
  • Johnson & Johnson (JNJ): Icotyde, for moderate-to-severe plaque psoriasis, saw weekly scripts edge up to 880. Management reports that over 18,000 prescriptions have been written for approximately 11,000 patients, with commercial insurance coverage now exceeding 50%.

Biosimilar Market Share Shifts

The report also shed light on the evolving competitive landscape for biosimilars, which are near-identical copies of original biologic drugs.

In the market for Stelara biosimilars, Biocon's Yesintek holds a dominant 78% share, while Amgen's (AMGN) Wezlana accounts for about 19%. For Prolia biosimilars, Sandoz's (SDZ) Jubbonti has captured a 26% share of total prescriptions, and Celltrion's Stoboclo holds about 14%. The original drug, Prolia, retains a majority share of approximately 53%.

Read next

More on Stocks
Back to latest news

LATEST